MBRX » Topics » Technologies

These excerpts taken from the MBRX 10-K filed Mar 17, 2008.

Technologies

        We are expanding our product pipeline by using our proprietary technologies, our knowledge of liver diseases and our expertise in pathways and proteins residing in the liver that significantly contribute to metabolic diseases. We have additional expertise in processes in the liver that are important for drug uptake, metabolism and excretion, all of which are important for targeting drugs to the liver with high specificity. We have used this knowledge to develop our proprietary NuMimetic and HepDirect technologies, which we use in several of our research programs. Our NuMimetic technology encompasses know-how and compound libraries that are useful in discovering molecules that bind effectively and specifically to nucleotide binding sites on certain key enzymes controlling important metabolic pathways. Our HepDirect technology is a proprietary technology used to target drugs to the liver. We also have expertise in structure-based drug design, and we have developed novel computational methods useful for predicting drug binding effectiveness and specificity. These methods have aided our design and discovery of novel drug compounds.

5


Technologies





        We are expanding our product pipeline by using our proprietary technologies, our knowledge of liver diseases and our expertise in pathways and proteins residing
in the liver that significantly contribute to metabolic diseases. We have additional expertise in processes in the liver that are important for drug uptake, metabolism and excretion, all of which are
important for targeting drugs to the liver with high specificity. We have used this knowledge to develop our proprietary NuMimetic and HepDirect technologies, which we use in several of our research
programs. Our NuMimetic technology encompasses know-how and compound libraries that are useful in discovering molecules that bind effectively and specifically to nucleotide binding sites
on certain key enzymes controlling important metabolic pathways. Our HepDirect technology is a proprietary technology used to target drugs to the liver. We also have expertise in structure-based drug
design, and we have developed novel computational methods useful for predicting drug binding effectiveness and specificity. These methods have aided our design and discovery of novel drug compounds.



5









EXCERPTS ON THIS PAGE:

10-K (2 sections)
Mar 17, 2008
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki